A Antinori,1 S Rusconi,2 N Gianotti,3 T Bini,4 D Mancusi,5 R Termini51HIV/AIDS Department, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS, Rome, Italy; 2Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan,
Antinori A +5 more
doaj
Physiologically Based Pharmacokinetic Modeling to Assess Antiretroviral-BTK Inhibitor Interactions and Provide Recommendations for Co-Administration Regimens. [PDF]
Chen L +5 more
europepmc +1 more source
Cobicistat/darunavir/cobicistat/darunavir/emtricitabine/tenofovir-alafenamide/darunavir/ritonavir [PDF]
openaire +1 more source
Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial. [PDF]
Català-Moll F +16 more
europepmc +1 more source
Effectiveness and safety of darunavir and lopinavir for treating children and adolescents living with HIV: a systematic review. [PDF]
O'Rourke J +10 more
europepmc +1 more source
Anion-Controlled Structural Interconversion of Palladium Cages Enables Separations by Selective Guest Capture and Release. [PDF]
Li Z, Ronson TK, McTernan CT.
europepmc +1 more source
Dosing of ritonavir-boosted darunavir for treatment of HIV in pregnancy. [PDF]
Sconza R +8 more
europepmc +1 more source
Virological outcomes with Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) in people previously treated with darunavir-based antiretroviral therapy. [PDF]
Sheridan R +6 more
europepmc +1 more source
Author Correction: Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial. [PDF]
Català-Moll F +16 more
europepmc +1 more source
Reversible Effects of Integrase Inhibitors on Newly Differentiated Adipocytes. [PDF]
Pickering RT +4 more
europepmc +1 more source

